Otonomy: A Core Buy In Biotech
Seite 6 von 9 Neuester Beitrag: 20.12.22 08:12 | ||||
Eröffnet am: | 19.01.17 12:24 | von: Balu4u | Anzahl Beiträge: | 208 |
Neuester Beitrag: | 20.12.22 08:12 | von: karlchen-trad. | Leser gesamt: | 69.978 |
Forum: | Hot-Stocks | Leser heute: | 23 | |
Bewertet mit: | ||||
Seite: < 1 | 1 | 2 | 3 | 4 | 5 | | 7 | 8 | 9 > |
gut - keine Frage - erwarte aber heute keinen großartigen Ausbruch
http://www.otonomy.com/pipeline/product-candidates/
Dem Kurs ist die News aber egal - ist vermutlich so erwartet worden
"This approval is an important milestone for the OTIPRIO program because it significantly expands the product's commercial potential to include approximately 4 million episodes of AOE per year in the United States, and broadens the target physician population beyond otolaryngologists to pediatricians and primary care physicians who treat the vast majority of AOE cases," said David A. Weber, Ph.D., president and CEO of Otonomy. “This indication also provides an entry point for OTIPRIO use in the office setting where the single-dose treatment can be administered by a physician or healthcare professional and then billed using an existing J Code. We look forward to incorporating AOE into our ongoing commercial partnering and divestiture discussions."
Das ist dann schon was faul